List of Excipients in Branded Drug PEPCID COMPLETE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kenvue Brands LLC	PEPCID COMPLETE	famotidine, calcium carbonate, and magnesium hydroxide	16837-246	ACACIA
Kenvue Brands LLC	PEPCID COMPLETE	famotidine, calcium carbonate, and magnesium hydroxide	16837-246	ALUMINUM OXIDE
Kenvue Brands LLC	PEPCID COMPLETE	famotidine, calcium carbonate, and magnesium hydroxide	16837-246	CELLULOSE ACETATE
Kenvue Brands LLC	PEPCID COMPLETE	famotidine, calcium carbonate, and magnesium hydroxide	16837-246	CORN SYRUP
Kenvue Brands LLC	PEPCID COMPLETE	famotidine, calcium carbonate, and magnesium hydroxide	16837-246	CROSPOVIDONE

Pepcid Complete Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Pepcid Complete combines famotidine with calcium carbonate and magnesium hydroxide in a chewable tablet. Its commercial value comes from a three-part product architecture: rapid antacid neutralization, longer acid suppression, and a convenient dosage form. The main excipient opportunity is not to alter the active ingredients, but to improve taste, mouthfeel, tablet robustness, mineral compatibility, stability, and manufacturing cost.

What is the active formulation of Pepcid Complete?

Pepcid Complete contains:

Component	Function	Label amount per tablet
Famotidine	H2-receptor antagonist	10 mg
Calcium carbonate	Antacid	800 mg
Magnesium hydroxide	Antacid	165 mg

The product is marketed as a chewable tablet for heartburn relief. The active load is approximately 975 mg before accounting for excipients, making compression, palatability, and tablet size central development constraints. The product label directs adults and children age 12 years and older to chew one tablet completely, with a maximum of two tablets in 24 hours. [1]

The formulation combines the rapid onset of antacids with the longer duration associated with famotidine. Calcium carbonate supplies relatively fast acid neutralization. Magnesium hydroxide contributes antacid capacity and helps balance the constipating tendency commonly associated with calcium-based antacids.

What excipient strategy supports Pepcid Complete?

The excipient system must solve five technical problems: mineral-heavy compression, bitter drug taste, chalky mouthfeel, moisture sensitivity, and dose uniformity.

Compression and tablet structure

The two antacid ingredients account for most of the tablet mass. A practical excipient platform may include:

• Microcrystalline cellulose as a dry binder and compression aid.
• Povidone or copovidone where additional binding strength is needed.
• Crospovidone or sodium starch glycolate to promote breakup after chewing and swallowing.
• Colloidal silicon dioxide to improve powder flow and reduce segregation.
• Magnesium stearate or another lubricant to control ejection force.
• Mannitol, sorbitol, or compressible sugar to improve mouthfeel and tablet density.

The formulation must avoid excessive lubricant levels. Hydrophobic lubrication can slow wetting and dissolution, while over-lubrication can reduce tablet tensile strength. That risk is more important in a chewable product because the tablet must be firm enough to survive packaging and transport but friable enough to break down readily during chewing.

Direct compression is commercially attractive because it reduces processing steps. However, calcium carbonate and magnesium hydroxide have different particle densities, flow profiles, and compaction behavior. Particle-size engineering, controlled premixing, and validated blending are therefore more important than simply increasing binder concentration.

Taste masking and mouthfeel

Famotidine has a bitter taste. Calcium carbonate can create a chalky or alkaline sensation, while magnesium hydroxide can produce a heavy mineral mouthfeel. The sensory system therefore has to mask both a low-dose bitter compound and a high-dose inorganic base.

Relevant excipient tools include:

• High-intensity sweeteners such as sucralose, acesulfame potassium, or aspartame, subject to product-specific labeling requirements.
• Polyols such as mannitol or xylitol for cooling sensation and bulk sweetening.
• Flavors selected for persistence after the tablet begins to disintegrate.
• Film-coated or granulated famotidine particles.
• Ion-exchange resins or polymeric taste-masking systems.
• pH-compatible flavor systems that do not degrade in the presence of alkaline mineral actives.

A key commercial distinction is whether taste masking is achieved through simple flavoring or through a proprietary particle-engineering process. Simple flavor systems lower development and regulatory risk but are easier for competitors to replicate. Coated drug particles, solid dispersions, or specialized granules can create stronger product differentiation, particularly if they improve taste without increasing tablet size.

Disintegration and antacid performance

Pepcid Complete is chewed before swallowing, so conventional disintegration is less important than rapid dispersion and dissolution of the drug fraction. The formulation still needs to release famotidine consistently and provide predictable acid-neutralizing capacity.

Superdisintegrants can improve dispersion, but excessive levels may create a gritty or rapidly swelling texture. Calcium carbonate and magnesium hydroxide can also alter local pH and interact with polymers, flavors, and coating materials. Development should evaluate:

• Famotidine dissolution across acidic and near-neutral media.
• Acid-neutralizing capacity using USP methods.
• Dispersion time after standardized chewing.
• Particle-size distribution after mastication.
• Uniformity of famotidine across the blend.
• Mineral segregation during hopper feeding and tableting.

The strongest formulation platform will treat famotidine release and antacid neutralization as separate performance targets rather than assuming that a single disintegrant system optimizes both.

Moisture and stability control

The primary stability risks include moisture uptake, flavor loss, changes in tablet hardness, and degradation or migration of taste-masking materials. Packaging is therefore part of the excipient strategy.

Commercial options include:

• High-barrier blister packaging.
• Induction-sealed bottles with desiccant.
• Moisture-resistant tablet coatings.
• Low-moisture manufacturing and controlled-humidity storage.
• Flavor systems with improved volatility control.

A lower-cost bottle format may be adequate for a stable formulation, but blister packaging can protect chewable tablets from humidity and improve unit-dose convenience. The packaging choice can also support premium positioning in travel, portable heartburn relief, and adherence-oriented formats.

What formulation patents could protect a Pepcid Complete competitor?

The most defensible intellectual-property opportunities are likely to involve formulation execution rather than the basic active-ingredient combination.

Taste-masking patents

Potential claim categories include:

• Famotidine particles coated with a polymeric barrier.
• Drug granules containing specific binders and sweeteners.
• Coated famotidine combined with mineral antacids.
• Flavor systems that maintain palatability under alkaline conditions.
• Granule structures that reduce direct contact between famotidine and the oral cavity.

These claims can be commercially useful if they define measurable coating levels, particle-size ranges, dissolution profiles, or sensory thresholds.

Chewable-tablet patents

Potential protection may cover:

• A tablet hardness range combined with rapid dispersion.
• Specific ratios of calcium carbonate, magnesium hydroxide, binder, and disintegrant.
• Low-weight or reduced-size tablets with equivalent acid-neutralizing capacity.
• Sugar-free formulations with defined polyol systems.
• Reduced-chalkiness compositions.
• Improved famotidine content uniformity in high-mineral blends.

The enforceability of broad excipient-ratio claims depends on whether the formulation produces a technically distinctive result. Claims limited to routine sweeteners, lubricants, or conventional fillers are more vulnerable to design-around and obviousness challenges.

Packaging and stability patents

Packaging-related claims could address:

• Moisture-barrier blister structures.
• Desiccant-integrated bottles.
• Flavor-retention systems.
• Stability of coated famotidine granules in high-alkaline tablets.
• Unit-dose packaging that preserves tablet friability and taste.

These rights may not block every competing chewable formulation, but they can raise manufacturing and packaging costs for a direct substitute.

What is the FDA regulatory status of Pepcid Complete?

Pepcid Complete is an OTC heartburn product regulated through the FDA OTC framework. Famotidine and antacid ingredients such as calcium carbonate and magnesium hydroxide are addressed through FDA OTC regulations and applicable monograph requirements. [2][3]

The regulatory pathway depends on the exact formulation and claims:

Development approach	Likely regulatory position
Same active ingredients, strengths, dosage form, and compliant labeling	OTC monograph pathway, if all requirements are met
New excipient system with no change to permitted claims	May remain within the monograph pathway, subject to formulation and manufacturing compliance
New dosage form, new active combination, or different claims	May require FDA review outside the standard monograph route
New pediatric use or expanded indication	Requires careful regulatory evaluation and supporting evidence
Novel delivery technology	Potential NDA or other FDA submission depending on the product design

The regulatory advantage of an OTC-monograph product is lower approval friction than a new prescription drug. The commercial constraint is that monograph-compliant competitors can enter without licensing the branded formulation owner.

What is the Orange Book status of Pepcid Complete?

Pepcid Complete is an OTC product and is not expected to have the same Orange Book listing structure as an approved prescription NDA product. The FDA Orange Book primarily identifies approved drug applications and associated patent and exclusivity information for prescription and certain approved nonprescription products. [4]

The absence of a conventional Orange Book patent listing does not mean the product has no intellectual-property protection. Relevant rights may include:

• Formulation patents.
• Taste-masking patents.
• Manufacturing-process patents.
• Packaging patents.
• Trademark rights.
• Trade secrets covering granulation, flavor systems, and process controls.

For a competitor, freedom-to-operate work should therefore examine USPTO records, assignment data, litigation databases, trademark filings, FDA labeling, and commercial product comparisons rather than relying only on Orange Book data.

When does Pepcid Complete lose exclusivity?

Pepcid Complete does not depend on a single patent expiry date in the same way as a patented prescription drug. Its practical exclusivity is based on brand recognition, retail placement, trademark rights, formulation know-how, packaging, and consumer loyalty.

The basic active combination is vulnerable to OTC competition because:

• Famotidine is an established generic active ingredient.
• Calcium carbonate and magnesium hydroxide are widely available antacids.
• The product is sold through the consumer-health channel.
• Monograph-based entry can reduce approval barriers.
• Retailers can substitute private-label or store-brand products.

A branded version can retain pricing power if it delivers superior taste, smaller tablets, faster perceived relief, better packaging, or stronger consumer recognition. A competitor with equivalent active ingredients but a materially better sensory profile could capture share without infringing a narrow formulation patent.

Which companies could challenge Pepcid Complete commercially?

The competitive field includes branded consumer-health companies, generic manufacturers, private-label retailers, and contract manufacturers.

Competitor group	Commercial advantage	Main constraint
Haleon and the Pepcid brand	Brand recognition, retailer access, consumer trust	Premium pricing and mature category
Generic OTC manufacturers	Lower cost and broad private-label distribution	Limited brand equity
Retail pharmacy chains	Strong shelf control and private-label economics	Dependence on retail traffic
Consumer-health companies	Marketing scale and portfolio cross-selling	Need to differentiate from established brands
Contract manufacturers	Rapid formulation and packaging deployment	Dependence on customers for brand investment

The closest substitutes include standalone famotidine products, calcium carbonate antacids, magnesium-containing antacids, alginate products, and proton-pump-inhibitor OTC products. Pepcid Complete competes on speed and duration rather than on maximum acid suppression.

What commercial opportunities exist for a new excipient platform?

Sugar-free and low-calorie chewables

A sugar-free product with improved texture could target consumers avoiding sucrose or seeking lower-calorie heartburn relief. Polyol selection must account for gastrointestinal tolerance, tablet cooling effect, hygroscopicity, and compression behavior.

Smaller tablets

Reducing tablet size is commercially attractive because the active load is high. Opportunities include porous mineral excipients, engineered calcium carbonate, higher-density granules, or improved famotidine loading. The product must preserve acid-neutralizing capacity while remaining easy to chew.

Faster sensory onset

Consumers often judge an antacid by how quickly the product begins to dissolve and relieve symptoms. Flavor release, rapid tablet breakup, and early famotidine availability can support a "fast relief" positioning, provided the claim is supported by appropriate testing and labeling review.

Better taste and reduced chalkiness

This is probably the most practical differentiation opportunity. A competitor that delivers a smoother mouthfeel, less alkaline aftertaste, and less residual grit can compete even with equivalent active ingredients.

Premium portable packaging

Blistered unit doses, child-resistant systems, and travel packs can support higher retail pricing. Packaging can also reduce moisture exposure and improve dose accountability.

Pediatric or age-specific formats

A lower-strength chewable or mini-tablet could target supervised use in younger populations, but pediatric claims and dosing require separate regulatory assessment. The formulation challenge includes taste sensitivity, tablet size, and safety labeling.

Combination-product line extensions

Potential extensions include:

• Famotidine with calcium carbonate alone.
• Famotidine with alginate or another barrier-forming antacid.
• Sugar-free and dye-free versions.
• Rapid-dissolve granules or oral powders.
• Chewable tablets with reduced mineral load.

Each extension creates a new patent and regulatory profile. The strongest commercial case is likely a formulation that improves consumer experience without introducing a complex administration method.

How strong is the Pepcid Complete patent estate?

The product’s practical competitive position is stronger than the likely protection around its basic active ingredients. The active combination is straightforward and exposed to OTC substitution. Defensible value is more likely to reside in execution:

1. Taste-masked famotidine particles.
2. Stable high-mineral chewable tablets.
3. Proprietary flavor and sweetener systems.
4. Manufacturing controls that maintain content uniformity.
5. Packaging that preserves moisture and sensory performance.
6. Trademarks and retail distribution.

A broad composition patent covering famotidine plus common antacids would face substantial validity and design-around pressure. Narrower patents tied to measurable performance, specialized particle architecture, or unusual stability results would have greater commercial relevance.

What generic launch risks exist for Pepcid Complete?

Generic and private-label entry can occur through several routes:

• Direct substitution with the same active ingredients.
• Separate sale of famotidine and antacid products.
• A lower-priced chewable combination.
• A different flavor or dosage form with the same heartburn-relief positioning.
• Retailer-owned products manufactured by third parties.

The principal barriers are not FDA approval exclusivity or API scarcity. They are consumer acceptance, shelf placement, flavor quality, tablet manufacture, and retailer economics. A new entrant can reduce risk by using established OTC actives and investing in taste-masking and packaging rather than pursuing a novel therapeutic mechanism.

Key Takeaways

• Pepcid Complete contains famotidine, calcium carbonate, and magnesium hydroxide in a chewable tablet.
• The central excipient challenge is combining bitter, alkaline, mineral-heavy actives with acceptable taste and mouthfeel.
• Microcrystalline cellulose, binders, superdisintegrants, glidants, lubricants, sweeteners, polyols, flavors, and taste-masking coatings are the main formulation tools.
• The best commercial opportunities are sugar-free products, smaller tablets, reduced chalkiness, improved flavor persistence, and moisture-protective packaging.
• Pepcid Complete is an OTC product, so conventional Orange Book exclusivity analysis is less useful than formulation, trademark, manufacturing, and packaging analysis.
• The basic active combination is relatively exposed to generic and private-label competition.
• Stronger patent opportunities would focus on taste-masked famotidine particles, tablet architecture, stability, sensory performance, and manufacturing processes.

FAQs

Can calcium carbonate and magnesium hydroxide be replaced in a Pepcid Complete-style formulation?

Yes. A developer could evaluate other antacid systems, including calcium carbonate alone, magnesium-containing combinations, alginates, or alternative mineral bases. The replacement would change acid-neutralizing capacity, taste, tablet size, labeling, and regulatory requirements.

Which excipient is most important for improving Pepcid Complete taste?

No single excipient controls taste. The strongest approach usually combines famotidine taste masking with a sweetener, flavor, and mouthfeel modifier. Particle coating or granulation can provide more durable masking than flavor alone.

Can a company market a generic Pepcid Complete without licensing Haleon?

A company may be able to market a compliant OTC product without a license if it does not infringe enforceable patents, trademarks, or other proprietary rights. The active ingredients themselves are established, but formulation and branding require separate freedom-to-operate analysis.

Is a chewable Pepcid Complete tablet suitable for direct compression?

It may be suitable, but the high mineral load creates flow, segregation, hardness, lubrication, and sensory challenges. Dry granulation or wet granulation may provide better control where direct compression produces unacceptable variability.

What is the highest-value patent claim for a Pepcid Complete competitor?

A claim covering a defined taste-masked famotidine particle or granule combined with the antacid system is likely to have greater strategic value than a claim limited to common excipients. Performance-linked claims involving dissolution, stability, texture, or taste can also improve differentiation.

References

1. DailyMed. (n.d.). Pepcid Complete chewable tablet: Famotidine, calcium carbonate, and magnesium hydroxide labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 331: Antacid products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/

3. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book